Add to ORKGDespite current standards of care aimed at achiev-ing targets for low-density lipoprotein (LDL) cho-lesterol, blood pressure and glycaemia, dyslipi-daemic patients remain at high residual risk of vascular events. Atherogenic dyslipidaemia, specifically elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol, often with elevated apolipoprotein B and non-HDL cholesterol, is common in patients with established cardiovascular disease, type 2 diabetes, obe
A panel of European experts on lipids and cardiovascular disease discussed clinical approaches to ma...
A panel of European experts on lipids and cardiovascular disease discussed clinical approaches to ma...
Objective: Timely recognition and optimal management of atherogenic dyslipidemia (AD) and residual v...
Despite achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure, and glycemi...
Despite current standards of care aimed at achieving targets for low-density lipoprotein (LDL) chole...
Despite achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure, and glycemi...
Despite current standards of care aimed at achieving targets for low-density lipoprotein (LDL) chole...
Reducing the risk of vascular events in patients with dyslipidaemia requires cardiovascular disease ...
Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of...
Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of...
Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of...
Background and aims: The maintenance of clinically recommended levels of low-density lipoprotein cho...
Residual vascular risk (RvR) represents risk of incident vascular events or progression of establish...
Cardiovascular disease poses a major challenge for the 21st century. Although good control of blood ...
Elevated low-density lipoprotein cho-lesterol (LDL-C) and elevated non– high-density lipoprotein cho...
A panel of European experts on lipids and cardiovascular disease discussed clinical approaches to ma...
A panel of European experts on lipids and cardiovascular disease discussed clinical approaches to ma...
Objective: Timely recognition and optimal management of atherogenic dyslipidemia (AD) and residual v...
Despite achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure, and glycemi...
Despite current standards of care aimed at achieving targets for low-density lipoprotein (LDL) chole...
Despite achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure, and glycemi...
Despite current standards of care aimed at achieving targets for low-density lipoprotein (LDL) chole...
Reducing the risk of vascular events in patients with dyslipidaemia requires cardiovascular disease ...
Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of...
Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of...
Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of...
Background and aims: The maintenance of clinically recommended levels of low-density lipoprotein cho...
Residual vascular risk (RvR) represents risk of incident vascular events or progression of establish...
Cardiovascular disease poses a major challenge for the 21st century. Although good control of blood ...
Elevated low-density lipoprotein cho-lesterol (LDL-C) and elevated non– high-density lipoprotein cho...
A panel of European experts on lipids and cardiovascular disease discussed clinical approaches to ma...
A panel of European experts on lipids and cardiovascular disease discussed clinical approaches to ma...
Objective: Timely recognition and optimal management of atherogenic dyslipidemia (AD) and residual v...